Effect of Androgen Deprivation Therapy on Cardiovascular Function in Prostate Cancer
Effect of Androgen Deprivation Therapy on Cardiovascular Function in Prostate Cancer
The aim of this project is to determine whether androgen deprivation therapy (ADT) decreases
 left ventricular function in prostate cancer patients. If found successful, this may lead to
 improved cardiovascular health via treatment and/or lifestyle interventions in prostate
 cancer populations.
Prostate Cancer is the second most common cancer among American men. Approximately 1 in 7 men
 will be diagnosed with prostate cancer during his lifetime. In prostate cancer patients
 alone, hypotestosteronemia, caused by prostate cancer treatment is associated with visceral
 adiposity, insulin resistance, metabolic syndrome, decreased high-density lipoprotein,
 increased low-density lipoprotein, increased triglycerides, loss of muscle mass, erectile
 disfunction, and a loss of microvascular endothelial function. Recently, several
 population-based studies have reported an association between androgen deprivation therapy
 and an increased risk of cardiovascular events, that include myocardial infarction and
 cardiovascular mortality. Given this link and the growing evidence that androgen-deprivation
 therapy adversely affects traditional risk factors, it is essential to better understand the
 role this type of treatment has on cardiac structure and function. As such, the manifestation
 of cardiovascular toxicities with prostate cancer treatment will initially be subclinical
 (left ventricular function changes in asymptomatic individuals) compared to clinical
 (including coronary symptoms or heart failure) and may develop subacutely (during treatment)
 or chronically.
Inclusion Criteria:

 -  Give voluntary consent to participate in the study

 -  (Group 1) Diagnosed prostate cancer patient/survivor with a history of androgen
 deprivation therapy treatment

 -  (Group 2) Diagnosed prostate cancer patient/survivor with no history of androgen
 deprivation therapy treatment

 -  (Group 3) Cancer free

 Exclusion Criteria:

 -  History of clinical cardiovascular disease (Atherosclerotic cardiovascular disease
 (ASCVD) defined by history of acute coronary syndromes, myocardial infarction (MI),
 stable or unstable angina, coronary or other arterial revascularization, stroke,
 transient ischemia attack (TIA), or peripheral arterial disease presumed to be of
 atherosclerotic origin)

 -  Not met the above criteria

 -  Unable to provide informed consent

 -  History of smoking (within 6 months) or current smoker

 -  Major signs or symptoms suggestive of cardiovascular, pulmonary, or metabolic disease.
 These include pain, discomfort in the chest, neck, jaw, arms or other areas that may
 result form ischemia; shortness of breath at rest or with mild exertion; Dizziness or
 syncope; Orthopnea or paroxysmal nocturnal dyspnea; ankle edema; palpitations or
 tachycardia; intermittent claudication; known heart murmur; unusual fatigue or
 shortness of breath with usual activities